Introduction
In the summer of 1993, the first international consensus conference on high-dose therapy with hematopoietic stem cell support (HDT) in hematologic malignancies and solid tumors was held in Lyon, France [1] . At that time, there were insufficient data to determine whether "HDT was either superior or significantly worse than conventional combination chemotherapy in any stage of non-Hodgkin's lymphoma (NHL)" [1] . In the intervening years, a number of Fandomized studies have been completed which address important questions regarding the role of HDT in the aggressive NHLs. For this reason, the original consensus conference organizers convened a second International Consensus Conference on HighDose Therapy with Hematopoietic Stem Cell Transplantation in Aggressive NHLs in April 1998 and charged a jury with the task of evaluating available data on when and how to perform HDT in these diseases ( Table 1) . The jury operated under standard consensus conference guidelines. For each question regarding HDT in aggressive NHLs, the jury made a positive or negative recommendation or indicated that there were insufficient data to make a recommendation ( Table 1 ). The quality of the evidence supporting each recommendation was also evaluated according to standard accepted criteria (Table 2 ) [2] .
When to transplant?

First or subsequent relapse
Chemosensitive relapse
The Jury was first asked to identify settings in which high dose therapy with hematopoietic stem cell support (HDT) was the recommended treatment option (Table 1) . Patients with chemosensitive first or subsequent relapses were thought to be appropriate candidates for HDT on the basis of the randomized prospective PARMA study (level 1 evidence, Table 2 ) [3, 4] . In this study, 109 patients with chemosensitive first or subsequent relapse who received consolidative HDT were more likely to remain disease-free than patients who were given additional conventional salvage therapy (five-year event-free survivals, 46% HDT vs. 12% conventional therapy, P = 0.001) [3] . Further analysis of the PARMA study suggested that patients who relapsed within 12 months of their initial diagnosis were less likely to benefit from HDT than patients who relapsed at later timepoints. In PARMA study patients, the Age-Adjusted International Prognostic Index (IPI) at relapse was also predictive for long-term outcome. Although patients with an IPI of 0 at relapse had comparable outcomes with HDT or conventional therapy, patients with IPIs of 1-3 at relapse were more likely to remain disease-free if they received consolidative HDT. The jury noted that the PARMA study only included patients with good performance status and no bone marrow involvement [3] . However, committee members believed that registry data (level 2 evidence, Table 2 ) also supported the use of HDT in Table 1 . 
Untested relapse
The jury next addressed the question of whether patients in first or subsequent relapse should receive additional conventional salvage therapy prior to HDT or proceed directly to HDT in untested relapse (Table 1 ). In the jury's opinion, the recently completed randomized prospective LNH-93-RP study (level 1 evidence) supported the use of additional salvage chemotherapy prior to HDT [5] . In LNH-93-RP, patients who received additional salvage therapy prior to HDT had more favorable overall survivals than those who proceeded to HDT in untested relapse (overall survivals, 38% (salvage therapy) vs. 21% (untested relapse), P = 0.00085) [5] .
Chemorefractory relapse and primary refractory disease
The appropriateness of HDT in patients with chemorefractory first or subsequent relapse or primary refractory disease was also assessed (Table 1 ) [4] . Interpretation of the data from different studies on HDT in primary refractory disease and chemorefractory relapse is hampered by the lack of uniform criteria to define chemorefractory disease [4, 6, 7] . For operative purposes, chemorefractory relapse was defined as stable or progressive disease following two cycles of an aggressive salvage regimen whereas primary refractory disease (induction failure) was defined as stable or progressive disease documented at restaging immediately following the completion of induction therapy. On the basis of their own clinical experience and earlier pilot studies [6] (level 3 evidence, Table 2 ), committee members felt that HDT was inappropriate in chemorefractory first or subsequent relapse. In contrast, registry data suggest that a small subset of patients with primary refractory disease may benefit from HDT (level 2 evidence) [7] . However, the jury expressed concern regarding the definition of primary refractory disease in this retrospective registry analysis [7] .
Induction therapy Induction therapy for newly diagnosed 'high-risk' disease
The jury next assessed data regarding the role of HDT in newly diagnosed patients who were less likely to be cured with standard combination chemotherapy [8] . In trials completed to date, these 'poor prognosis' patients were identified using a variety of clinical parameters [8] .
Several recent randomized prospective trials have compared upfront HDT to conventional induction therapy in 'poor prognosis' patients. However, these studies differed in both their design and conclusions. These differences in trial design and conclusions led the jury to characterize existing data as conflicting level 4 evidence (Table 2 ) and to recommend additional definitive studies. Currently available randomized phase III studies of HDT in newly diagnosed 'high-risk' patients include: 1) LNH-87 [9] ; 2) the Italian Non-Hodgkin's Lymphoma Study Group Trial [10] ; 3) LNH-93 [11] ; 4) the German High Grade Lymphoma Study Group Trial [12] ; and 5) the Milan trial [13] . In these studies, the role of HDT is assessed following full course standard induction therapy or abbreviated standard induction therapy or as upfront induction therapy.
HDT following full course standard induction therapy LNH-87 is one of the largest randomized prospective trials reported to date. In this study, 542 patients who were less than 55 years of age with at least one adverse prognostic factor and a complete response to full course standard induction therapy were randomized to receive additional high-dose therapy and autologous bone marrow transplantation or additional conventional dose therapy [9, 14] . In the initial analysis of all study patients, there were no treatment-related differences in three-year overall survival (56% three-year disease-free survival for both treatment arms) [14] . However, treatment-related differences became apparent when study patients were retrospectively grouped into low, lowintermediate, and high-intermediate/high-risk groups according to the age-adjusted International Prognostic Index (IPI) [9, 14] -. In the updated analysis of patients followed for a median of 53 months, 'low-risk' and 'lowintermediate risk' patients had similar outcomes when treated with either of the two regimens [9] . In contrast, 'high-intermediate/high-risk' patients had increased disease-free and overall survivals when they were treated with the high-dose experimental regimen (five-year DFS, experimental vs. standard therapy, 57% vs. 36% P -0.01; five-year overall survival, experimental vs. standard therapy, 65% vs. 52%, P = 0.06) [9] .
The Italian Non-Hodgkin's Study Group trial included 124 patients less than 60 years of age with bulky (> 10 cm) stage II or stage III-IV disease. Patients were randomized at study entry to receive standard induction therapy alone or the same regimen followed by autologous bone marrow transplantation (ABMT) [10] . Patients who were randomized to receive standard induction therapy and achieved a CR were simply followed; patients who obtained a partial response, no response or relapse underwent conventional salvage therapy [10] . Patients randomized to standard induction therapy and ABMT were restaged following their initial induction therapy; however, complete, partial and non-responders proceeded to ABMT. With a median follow-up of 42 months, the six-year overall survivals were identical (65%) in the two treatment arms [10] . However, when outcome was analyzed on the basis of age-adjusted IPI at diagnosis, patients with 'high-intermediate' or 'high risk' disease were more likely to remain disease-free if they received additional high dose therapy (three-year DFS 87% [HDT] vs. 48% [standard therapy], P = 0.008) [10] .
Retrospective analyses of the LNH-87 and Italian Study Group trials appear to support the use of consolidative HDT in high-intermediate or high-risk (IPI) patients who have completed standard dose induction therapy. However, additional randomized trials in which patients received abbreviated standard induction therapy and subsequent HDT reach different conclusions.
HDT following abbreviated standard induction therapy
In the recently completed LNH-93 trial, 370 patients with high-intermediate and high risk disease (according to the age-adjusted IPI) were randomized at diagnosis to receive standard induction therapy or three cycles of abbreviated induction therapy followed by HDT [11] . In the initial analyses of LNH-93, patients who underwent full-course conventional induction therapy actually had better outcomes than patients who received early HDT. With median follow-up of 30 months, the event-free and overall survivals for patients receiving full-course conventional induction therapy and early HDT were 54% and 63% (conventional induction therapy) vs. 41% and 47% (early HDT), /"-values 0.01 and 0.003, respectively [11] .
In a similarly designed recent study, the German High-Grade Lymphoma Study Group randomized 312 patients who were less than 60 years of age with an elevated LDH to receive either five cycles of standard induction therapy or three cycles of standard induction therapy followed by HDT [12] . In initial analyses, the two-year overall survivals of patients in the two treatment arms were comparable.
Up-front high-dose induction therapy
Another experimental approach to the treatment of high-risk patients is to intensify their initial induction therapy [13, 15, 16] . In a recent study from Milan, 98 patients with bulky or advanced stage disease were randomized at diagnosis to receive standard induction therapy or 'high-dose sequential therapy' consisting of single agent high dose cyclophosphamide, methotrexate, and etoposide followed by L-PAM/total body irradiation with bone marrow/peripheral blood stem cell rescue [13] . In this small phase III study, patients who received highdose sequential therapy had superior event-free survivals (seven-year event-free survivals, 76% [high-dose sequential therapy] vs. 49% [standard induction therapy], P = 0.004). However, overall survivals were not significantly different in the two treatment groups (overall survival 73% [high-dose sequential therapy] vs. 62% [standard induction therapy], P = NS, median follow-up 43 months) due to early treatment-related toxicity and the study's crossover design [13] .
Comparison of the published phase HI studies on HDTin newly diagnosed patients
It is of interest that the three 'positive' randomized trials [9, 10, 13] included full-course standard induction therapy followed by HDT or upfront high dose induction therapy whereas the two 'negative' studies [11, 12] contained abbreviated (three-cycle) standard induction therapy and early HDT. In addition, LNH-87 only included patients who had achieved a CR with standard induction therapy whereas LNH-93, the Italian and German Study Group trials and the Milan study included newly diagnosed untreated patients.
Additional ongoing studies
There are several ongoing randomized trials of HDT in newly diagnosed poor prognosis patients with aggressive lymphoma. All of these studies utilize one of the abovementioned treatment strategies. In the Swiss Group for Clinical Cancer Research (SAKK) Mistral 2 and a European Organization for Research and Treatment of Cancer (EORTC) study, patients receive full course induction therapy and undergo subsequent restaging. Responding patients are then randomized to undergo immediate HDT or HDT at relapse. In SAKK Mistral 1, patients are randomized at diagnosis to receive high-dose sequential therapy [13] or full-course standard induction therapy.
An additional United Kingdom Lymphoma Group (UKLG)/Australia New Zealand (ANZ)/Nordic European Bone Marrow Transplantation Group (EBMT) trial has an experimental design that is similar to that of the recently completed LNH-93 [11] and German [12] studies. In the UKLG/ANZ/Nordic EBMT study, patients are randomized at diagnosis to receive abbreviated standard induction therapy followed by HDT or full course standard induction therapy.
The jury felt that these additional trials of HDT in newly diagnosed poor prognosis patients will provide further insights regarding the benefits of this approach. Specifically, committee members believed that these studies will clarify the need for a prior response to standard induction therapy, the benefit of full-course standard induction therapy and the value of high dose induction therapy.
Selection criteria for future front-line HDT trials
In one recently completed (LNH-93 [11] ) and an additional ongoing randomized trial (UKLG/ANZ/Nordic/ EBMT), study patients were selected on the basis of their age-adjusted IPI risk group; eligible patients had either 'high-intermediate' or 'high-risk' disease. The retrospective analyses of LNH-87 and the Italian Study Group Trial also suggested that the benefit of HDT was limited to patients with high-intermediate or high-risk (age-adjusted IPI) disease (level 1-2 evidence) [9, 10] . For these reasons, the jury concluded that patients who fell into 'high-intermediate' and 'high-risk' categories of the age-adjusted IPI were the most appropriate candidates for future upfront HDT studies ( Table 1) . The jury also supported the identification of other potentially useful prognostic factors at diagnosis; however, they did not feel that other selection criteria were ready to be incorporated into large-scale studies at the present time.
Response criteria
•• To compare recently completed and ongoing randomized phase III trials of H D T in responding patients, the jury also felt that it was essential to adopt uniform definitions of response. Committee members welcomed the ongoing international effort to standardize response criteria for non-Hodgkin's lymphomas [17] . In the interim, the jury agreed that complete responses required the disappearance of all evidence of disease on standard radiographs, physical examination and bone marrow aspirate and biopsy. It was more difficult to accurately delineate complete responders with residual masses from partial responders with persistent viable tumors. The jury strongly encouraged additional investigation into imaging techniques that might distinguish fibrotic residual masses from those containing viable tumor [18] . Nevertheless, committee members acknowledged that such imaging techniques (gallium and/or PET scans) are not widely available at the present time. For this reason, current definitions of response continue to be based on routine radiographic studies.
Slow or incomplete responses to standard induction therapy
As noted above, jury members felt that it was difficult to distinguish complete responders with residual masses from partial responders with persistent viable tumor using standard radiographic criteria. This was a major point of concern when the two randomized studies on the role of HDT in patients with slow or incomplete responses to standard induction therapy were considered (Table 1) [19, 20] .
In a Dutch cooperative group trial, 69 patients with aggressive NHL in partial response following three cycles of CHOP were randomized to receive HDT or complete an additional five cycles of CHOP [19] . Fouryear disease-free and overall survivals were similar in the two treatment arms (41% and 60% [HDT] versus 72% and 85% [full course CHOP], P = NS) [19] . However, as noted at the consensus conference, the study sample size was too small, the treatment arms were imbalanced with regard to known clinical prognostic factors and the trial included few 'high-intermediate' or 'high-risk' (IPI) patients.
An Italian multicenter study compared the efficacy of HDT to conventional salvage therapy in 49 aggressive NHL patients in partial response following 2/3 of their planned induction therapy [20] . Although progressionfree and overall survivals favored the HDT arm (73% and 73% [HDT] versus 52% and 59% [conventional salvage therapy]), these differences were not statistically significant [20] . However, the conference reviewer noted that this study was also too small because ~ 260 randomized patients would be needed to demonstrate a 33% difference in relative risk between the two treatment arms. The above-mentioned methodological issues in the two available randomized studies (level 4 evidence, Table 2 ) led the jury to conclude that the role of HDT in slow or incomplete responses remains to be defined ( Table 1) .
How to transplant?
After evaluating the settings in which HDT was indicated (When to transplant), the jury next assessed the optimal way to administer HDT (How to transplant, Table 1 ).
High-dose regimens
In the absence of randomized studies comparing specific regimens, the jury concluded that there was not a single superior high dose protocol (Table 1 ) [21] . The absence of randomized prospective trials made it impossible to determine whether TBI-containing regimens were superior to drug-only programs [21] . Available data on currently utilized regimens were primarily derived from well-designed single-arm studies, single institution trials or registries (level 2 evidence).
Hematopoietic stem cell sources
In the jury's opinion, recently completed randomized trials and an earlier case-controlled study supported the use of autologous mobilized peripheral blood stem cells (PBSC) rather than bone marrow in HDT studies (level 1 evidence, Table 1 ) [22] [23] [24] [25] [26] . In a case-controlled analysis, 83 lymphoma patients who received PBSC autografts were compared with 83 additional lymphoma patients who received autologous BM [23] . Patients who were autografted with PBSC had more rapid hematopoietic recovery and fewer episodes of interstitial pneumonitis and fungal infection than those who received BM [23] .
In an additional randomized trial, 58 patients with Hodgkin's disease or non-Hodgkin's lymphoma who were undergoing HDT received either autologous BM or mobilized PBSC [24] . Time to platelet and neutrophil recovery were significantly shorter in patients receiving PBSC (duration thrombocytopenia 16 days [PBSC] vs. 23 days [ABMT], P = 0.02; duration neutropenia 11 days [PBSC] vs. 14 days [ABMT], P = 0.005) [24] .
Autologous bone marrow and mobilized PBSC support were also compared in a phase HI trial of lymphoma and solid tumor patients undergoing HDT [25] . Hematologic recovery was more rapid in patients who received mobilized PBSC than in those who received BM (duration thrombocytopenia 16 days [PBSC] vs. 36 days [BM] , P = 0.001) [25] .
Similar results were obtained in an additional phase III study in which 89 patients with relapsed or newly diagnosed high-risk intermediate grade lymphoma were randomized to receive autologous BM or mobilized PBSC following HDT [26] . In this trial, median times to neutrophil recovery for patients receiving PBSC or BM were 10 days or 16 days, respectively (P = 0.0013) [26] .
Although the above-mentioned trials support the use of mobilized PBSC rather than unprimed BM, a randomized study of mobilized PBSC versus mobilized BMT in lymphoma patients undergoing HDT suggests that primed BM is as effective as mobilized PBSC in hematologic reconstitution [27] .
The jury believed there to be insufficient data regarding the potential utility of allogeneic stem cell support in aggressive NHLs (level 4 evidence) [22] . Nevertheless, committee members felt that the potential graft vs. lymphoma effects associated with allogeneic stem cell transplantation warranted further study. The jury also believed that there were insufficient data regarding the utility of umbilical cord stem cell transplantation in aggressive NHLs (level 4 evidence) [22] .
Stem cell mobilization
Committee members agreed that available phase II studies and registry data supported the use of chemotherapy plus cytokines to mobilize hematopoietic stem cells (level 2 evidence) [22] . However, they acknowledged that the use of cytokines alone might be warranted in specific clinical settings (level 3 evidence). Similarly, the jury noted that a supplemental ('back-up') marrow might be appropriate in rare individual settings (level 3 evidence).
Purging or positive selection
The jury acknowledged single institution data regarding the potential benefits of purging autologous BMs in follicular lymphoma patients undergoing HDT [28] . However, committee members also noted a case-matched registry series in which NHL patients undergoing HDT received purged or unpurged BMs and had comparable progression-free survivals [29] . In an additional single institution report, NHL patients who received histologically negative BMs with minimal tumor cell contamination had shorter relapse-free survivals following HDT [30] . At the present time, committee members felt that there were insufficient data (level 4 evidence) to recommend routine purging or positive selection of stem cell products in the aggressive lymphomas. Nevertheless, the group recommended further rigorous analysis of this area.
The jury also addressed a final series of questions regarding the role of HDT in specific clinical settings.
Chemosensitive marrow involvement at relapse
Committee members believed that single institution data and registry studies supported the use of HDT in patients with chemosensitive bone marrow involvement at relapse. However, the jury noted that most studies evaluated autologous stem cell transplants in this setting [31] (level 2 evidence, Table 1) and that there was little additional data on comparable allogeneic stem cell transplants (level 4 evidence).
HLA-matched sibling allogeneic transplants
The jury believed there to be insufficient data on the value of matched sibling allogeneic transplants in patients with recurrent disease following autologous transplant (level 4 evidence, Table 1 ) or in young patients in first relapse (level 4 evidence). Nevertheless, they felt that these areas warranted further study.
Future directions
In the jury's opinion, first or subsequent chemosensitive relapse was an excellent setting in which to evaluate potential improvements in the administration of HDT. Given the demonstrated efficacy of the high dose regimen used in the PARMA study [3] , such HDT would be an appropriate control arm in future comparative trials of novel regimens, additional forms of radiotherapy, or different sources of hematopoietic stem cells. First or subsequent chemosensitive relapse would also be an appropriate setting to compare autologous vs. allogeneic stem cell support, include immunotherapy of minimal residual disease [32, 33] , or study novel mobilization regimens containing additional cytokines such as stem cell factor or FLT 3 ligand [22] .
In newly diagnosed patients, the jury felt that the first priority was to determine the benefit of HDT. Committee members were optimistic that ongoing randomized studies would help clarify the role of HDT in newly diagnosed poor prognosis patients.
The jury also advocated the collection of tumor specimens from newly diagnosed patients for future analyses of biologic prognostic factors that might refine and improve the International Prognostic Index and provide additional insights into novel therapeutic targets.
